# Survival-Prediction-in-Advanced-Breast-Cancer
This study analyzed 2,622 efficacy endpoints from 892 phase II trials in advanced breast cancer to develop decision tree and random forest models to predict median progression-free survival and median overall survival from aggregate trial-level characteristics.
